Open AccessEvaluation of autoantibodies and immunoglobulin G subclasses in women with suspected macroprolactinemia
Author(s) -
Yu Chao,
Fan Fei,
Hu Siqi,
Meng Lingxin,
Xu Dong,
Wang Juan,
Chen Lu,
Liu Jingrui,
Dong Ying,
Lu Yifan,
Shen Min,
Zhai Yanhong,
Cao Zheng
Publication year - 2020
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.23456
Subject(s) - autoantibody , medicine , antibody , immunology , anti thyroid autoantibodies , immunoglobulin g , anti nuclear antibody , prolactin , subclass , asymptomatic , gastroenterology , hormone
Background Macroprolactin mostly composed of an immunoglobulin G (IgG) and a monomeric prolactin (PRL) represents the major circulating PRL form in the patients with macroprolactinemia that are usually asymptomatic and may not require treatment. In this study, we aimed to evaluate the prevalence of antithyroid and antinuclear antibodies, as well as the IgG subclass distributions in the patients suspected for macroprolactinemia. Methods From January to July in 2018, totally 317 patients with elevated PRL were subjected to the polyethylene glycol (PEG) precipitation assay. The patients with recovery rates of ≤60% were subjected for IgG subclass determination and autoantibody testing including thyroid peroxidase antibody (aTPO), antithyroglobulin antibody (aTG), and antinuclear antibodies (ANA). Results The higher the post‐PEG PRL recovery rates, the less typical hyperprolactinemia symptoms and the higher prevalence of autoantibodies were observed. The IgG1 and IgG3 were the predominant subclasses in the PRL‐IgG complexes according to the immunoprecipitation experiments. Conclusion The patients with post‐PEG PRL recovery rates of <40% and 40%‐60% were likely to represent two distinct populations of different clinical presentations. The prevalence of autoantibodies and IgG subclasses distribution suggested their pathogenic significance in the development of macroprolactinemia.